The trial that's being highlighted as impacted by recruitment is the PTX-200 trial which is located in at least one US clinic, Unique.
Suspect keeping the trial ongoing and patients literally alive will work in our favour. Terminating the trial when there are patients benefitting from the treatment and garnering further data can only but provide what is needed in pursuing a collaborator. Its certainly reaching its end of use-by-date for our expenditure capacity... particularly when CellPryme has sort of taken up the gauntlet with far mor immediate revenue potential.
Should you be referrig to PTX-100, then yes, looking to the US (or even Asia) would make sense IF recruitment is proving difficult here for different reasons. I'd like to see our connections with ACTRIS in Singapore to play out for PTX across all our therapies, TBH.
